Achieving remission of proteinuria in childhood CKD
暂无分享,去创建一个
[1] G. Remuzzi,et al. Progression, Remission and Regression of Chronic Renal Diseases , 2016, Nephron.
[2] G. Remuzzi,et al. Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. , 2016, Journal of the American Society of Nephrology.
[3] G. Remuzzi,et al. A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study , 2015, Nephron.
[4] P. Peduzzi,et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.
[5] H. Pan,et al. Standardizing Anthropometric Measures in Children and Adolescents with Functions for Egen: Update , 2013 .
[6] S. Shahinfar,et al. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome , 2013, Pediatric Nephrology.
[7] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.
[8] G. Remuzzi,et al. Mechanisms and treatment of CKD. , 2012, Journal of the American Society of Nephrology : JASN.
[9] S. Shahinfar,et al. Losartan and enalapril are comparable in reducing proteinuria in children. , 2012, Kidney international.
[10] G. Remuzzi,et al. Proteinuria should be used as a surrogate in CKD , 2012, Nature Reviews Nephrology.
[11] Harvey Goldstein,et al. REALCOM-IMPUTE Software for Multilevel Multiple Imputation with Mixed Response Types , 2011 .
[12] Remission Clinic Task Force. The Remission Clinic approach to halt the progression of kidney disease. , 2011, Journal of nephrology.
[13] J. Ingelfinger. Blood-pressure control and delay in progression of kidney disease in children. , 2009, The New England journal of medicine.
[14] A. Anarat,et al. Strict blood-pressure control and progression of renal failure in children. , 2009, The New England journal of medicine.
[15] G. Remuzzi,et al. Proteinuria: Is the ONTARGET renal substudy actually off target? , 2009, Nature Reviews Nephrology.
[16] G. Remuzzi,et al. Proteinuria: Increased angiotensin-receptor blocking is not the first option , 2009, Nature Reviews Nephrology.
[17] E. Burgess,et al. Supramaximal dose of candesartan in proteinuric renal disease. , 2009, Journal of the American Society of Nephrology : JASN.
[18] Susan L Furth,et al. New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.
[19] G. Remuzzi,et al. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[20] G. Remuzzi,et al. Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.
[21] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[22] Jing Cheng-xue. Epidemiology of Chronic Kidney Disease in Children , 2008 .
[23] M. Panteghini. Enzymatic assays for creatinine: time for action. , 2008, Clinical chemistry and laboratory medicine.
[24] A. Bomback,et al. The incidence and implications of aldosterone breakthrough , 2007, Nature Clinical Practice Nephrology.
[25] G. Remuzzi,et al. Time to abandon microalbuminuria? , 2006, Kidney international.
[26] Wilfried De Backer,et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. , 2006, Metabolism: clinical and experimental.
[27] G. Remuzzi,et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.
[28] G. Remuzzi,et al. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.
[29] G. Remuzzi,et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. , 2003, Kidney international.
[30] B. Brenner,et al. Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion , 2001, Nephron.
[31] G. Remuzzi,et al. Progression, remission, regression of chronic renal diseases , 2001, The Lancet.
[32] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[33] G. Remuzzi,et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.
[34] P. Ruggenetu. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) , 1998 .
[35] G. Ruocco,et al. Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up , 1997, Pediatric Nephrology.
[36] T. Greene,et al. Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.
[37] T. Greene,et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. , 1995, Annals of internal medicine.
[38] H. Trachtman,et al. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. , 1988, The Journal of pediatrics.
[39] S. Poucell,et al. Focal segmental glomerulosclerosis with idiopathic nephrotic syndrome: three types of clinical response. , 1982, The Journal of pediatrics.